This version of the registration was submitted prior to the Lobbying Transparency Act coming into force on May 4, 2020. Due to different information requirements at that time, the registration is presented in the following format.
Registration ID: 470133 Submitted by lobbyist on: April 1, 2015 09:25:53 AM Accepted by Registrar on: April 13, 2015 08:27:12 AM
Designated Filer Information
Landau, Dr. Craig
575 Granite Court
Pickering, ON, L1W 3W8
905-420-6400
Canada
Organization Information
Purdue Pharma Inc
Purdue Pharma is a research-based pharmaceutical company in Pickering, Ontario. Purdue Pharma (Canada) (www.purdue.ca) is committed to improving patient health and well-being by developing innovative medicines and supporting quality education for the safe use of its products. Purdue is a recognized leader in research and development of products for the treatment of pain. Its portfolio of products also includes medication for the treatment of attention deficit hyperactivity disorder (ADHD), respiratory disease, gastrointestinal disorders and infection control.
575 Granite Court
Pickering, ON, L1W 3W8
905-420-6400
Canada
Relevant Affiliates
The client has no relevant affiliates.
Government or Government Agency Funding
The organization does not receive any funding from a government or government agency.
Other Controlling or Directing Interests
The organization has no other controlling or directing interests.
Active Registration Period
April 1, 2015
September 28, 2015
Organization's In-House Lobbyists
Name:
Gaskin, Howard
April 11, 2015
Inactivation Date:
September 29, 2015
BC Public Office Background
This individual has not held any public office positions in BC.
Lobbying Activities
Health
Development, establishment, amendment or termination of any program, policy or decision
Subject matter for meetings would include (1) responsible prescribing of medication, in particular prescription opioids for pain management, (2) development of appropriate access to such medications for legitimate pain patients, while restricting access for inappropriate patients, (3) the value of Abuse Deterrent Formulations as a means of reducing harms associated with prescription medications (in particular, preventing the development of addiction and preventing abuse of prescription medications by non-patients), (4) efforts to collaboratively achieve the above goals in an economically responsible way, and provide the BC government with certainty in this area of their drug budget, and (5) preparation for the introduction of new generations of existing medications, particularly in pain management and in ADHD management.
Target Contacts
Target Type
Name
Title or Constituency
Date Added
Staff of Minister
Minister of Health
April 11, 2015
Minister
Anton,
Suzanne
Minister of Justice and Attorney General
April 11, 2015
Minister
Lake,
Terry
Minister of Health
April 11, 2015
Public Agency
Health
April 11, 2015
Name:
Spigelman, Aleina
April 1, 2015
Inactivation Date:
September 29, 2015
BC Public Office Background
This individual has not held any public office positions in BC.
Lobbying Activities
Health
Development, establishment, amendment or termination of any program, policy or decision
Subject matter for meetings would include (1) responsible prescribing of medication, in particular prescription opioids for pain management, (2) development of appropriate access to such medications for legitimate pain patients, while restricting access for inappropriate patients, (3) the value of Abuse Deterrent Formulations as a means of reducing harms associated with prescription medications (in particular, preventing the development of addiction and preventing abuse of prescription medications by non-patients), (4) efforts to collaboratively achieve the above goals in an economically responsible way, and provide the BC government with certainty in this area of their drug budget, and (5) preparation for the introduction of new generations of existing medications, particularly in pain management and in ADHD management.
